Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$111.75M+91.2%$111.04M+55.0%$91.6M+54.6%$59.29M+2.9%$58.44M-6.8%
$214.14M+25.7%$204.18M+26.5%$193.54M+20.8%$180.93M+9.6%$170.32M+11.5%
$74.23M+40.9%$68.67M+42.5%$67.46M+49.5%$67.28M+56.6%$52.69M+28.9%
$251.68M+53.9%$240.31M+43.3%$224.02M+37.6%$185.58M+8.9%$163.49M-5.6%
$5.03M-4.3%$4.95M-11.1%$4.95M-11.9%$5.28M-9.4%$5.26M-9.0%
$22.86M0.0%$22.86M0.0%$22.86M0.0%$22.86M0.0%$22.86M0.0%
$85.37M-11.3%$88.08M-11.0%$90.79M-10.7%$93.5M-10.4%$96.21M-10.1%
$392.01M+24.3%$383.53M+18.7%$370.19M+15.3%$334.69M+0.9%$315.45M-6.3%
$11.47M+80.5%$3.08M+34.3%$6.53M-12.4%$9.46M+63.2%$6.35M-10.5%
$118.59M+24.7%$109.57M+9.1%$116.2M+27.7%$95.17M+26.1%$95.07M+30.1%
$221.22M+1.6%$220.34M+1.5%$219.47M+1.5%$218.63M-5.1%$217.81M-5.2%
$379M+8.1%$369.84M+4.9%$371.05M+6.2%$353.99M+0.8%$350.58M+1.4%
$18K+12.5%$17K+13.3%$17K+13.3%$16K+6.7%$16K+6.7%
-$669.07M+1.8%-$671.31M+0.1%-$682.39M-2.3%-$683.01M-4.9%-$681.08M-7.1%
$13.01M+137%$13.69M+146%-$861K+97.0%-$19.3M-0.1%-$35.13M-283%
$392.01M+24.3%$383.53M+18.7%$370.19M+15.3%$334.69M+0.9%$315.45M-6.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Xeris Biopharma Holdings, Inc.'s total assets?
Xeris Biopharma Holdings, Inc. (XERS) holds $392.0M in total assets, up 24.3% year over year.
How much debt does Xeris Biopharma Holdings, Inc. have?
Xeris Biopharma Holdings, Inc. carries $258.6M in total debt against $13.0M of shareholders' equity, a debt-to-equity ratio of 19.87.
How much cash does Xeris Biopharma Holdings, Inc. have?
Xeris Biopharma Holdings, Inc. holds $111.8M in cash and equivalents.
Can Xeris Biopharma Holdings, Inc. cover its short-term obligations?
Its current ratio is 2.12 — current assets exceed current liabilities.
Where does Xeris Biopharma Holdings, Inc.'s balance sheet data come from?
Every line is extracted from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.